Measurement of Gastric Residual Volume via Ultrasound after Receiving Intravenous Ondansetron, Metoclopramide, and Neostigmine in Critically Ill Patients: A Double-Blind Clinical Trial.
Gastric residual volume
Metoclopramide
Neostigmine
Ondansetron
Journal
Tanaffos
ISSN: 1735-0344
Titre abrégé: Tanaffos
Pays: Iran
ID NLM: 101308232
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
27
12
2020
accepted:
11
06
2021
entrez:
21
10
2022
pubmed:
1
4
2021
medline:
1
4
2021
Statut:
ppublish
Résumé
Gastric residual volume (GRV) is considered an important parameter for gastric emptying and nutrition tolerance. This volume is measured before any nutrition and has a direct effect on the volume and timing of the next nutrition. The present study aimed to examine the GRV via ultrasound after receiving intravenous ondansetron, metoclopramide, and neostigmine. In the present study, 40 patients were included in the study, 10 patients were excluded from the study due to death during treatment, and 30 patients were divided into three groups of 10(10 patients in each group).The first, second, and third groups received 2.5, 10, and 8 mg neostigmine, metoclopramide, and ondansetron every 8 h, respectively. The drugs were infused as a micro set in 100 ml normal saline into patients within 30 min. The patients underwent ultrasound imaging and GRV measurement by an intensive care unit (ICU) subspecialty fellow, who was not aware of the drugs received by the patients, in the 1 A total of 40 patients entered the study based on inclusion and exclusion criteria. The effect of neostigmine on reducing GRV (Gastric residual volume) in ICU patients was better than those of the other two drugs, which was significant. The results of this study showed that neostigmine has a better and significant effect on reducing GRV in ICU patients, compared to those of ondansetron and metoclopramide.
Sections du résumé
Background
UNASSIGNED
Gastric residual volume (GRV) is considered an important parameter for gastric emptying and nutrition tolerance. This volume is measured before any nutrition and has a direct effect on the volume and timing of the next nutrition. The present study aimed to examine the GRV via ultrasound after receiving intravenous ondansetron, metoclopramide, and neostigmine.
Materials and Methods
UNASSIGNED
In the present study, 40 patients were included in the study, 10 patients were excluded from the study due to death during treatment, and 30 patients were divided into three groups of 10(10 patients in each group).The first, second, and third groups received 2.5, 10, and 8 mg neostigmine, metoclopramide, and ondansetron every 8 h, respectively. The drugs were infused as a micro set in 100 ml normal saline into patients within 30 min. The patients underwent ultrasound imaging and GRV measurement by an intensive care unit (ICU) subspecialty fellow, who was not aware of the drugs received by the patients, in the 1
Results
UNASSIGNED
A total of 40 patients entered the study based on inclusion and exclusion criteria. The effect of neostigmine on reducing GRV (Gastric residual volume) in ICU patients was better than those of the other two drugs, which was significant.
Conclusion
UNASSIGNED
The results of this study showed that neostigmine has a better and significant effect on reducing GRV in ICU patients, compared to those of ondansetron and metoclopramide.
Types de publication
Journal Article
Langues
eng
Pagination
312-318Informations de copyright
Copyright© 2021 National Research Institute of Tuberculosis and Lung Disease.
Références
JPEN J Parenter Enteral Nutr. 2008 Jul-Aug;32(4):412-9
pubmed: 18596312
Hepatogastroenterology. 2008 Jan-Feb;55(81):294-7
pubmed: 18507128
Postgrad Med J. 2005 Oct;81(960):629-36
pubmed: 16210458
Dig Dis Sci. 1994 Dec;39(12 Suppl):91S-94S
pubmed: 7995225
Bratisl Lek Listy. 2011;112(6):309-13
pubmed: 21692403
Nutr Clin Pract. 2017 Apr;32(2):206-211
pubmed: 28362573
Eur J Pharmacol. 1997 May 30;327(2-3):189-93
pubmed: 9200559
J Res Med Sci. 2013 Sep;18(9):750-4
pubmed: 24381616
Neurogastroenterol Motil. 2015 Dec;27(12):1736-46
pubmed: 26387781
Gut. 1992 Jan;33(1):115-7
pubmed: 1740267
Pharmacotherapy. 2000 Dec;20(12):1486-98
pubmed: 11130221
Neurogastroenterol Motil. 2014 Jun;26(6):851-61
pubmed: 24750304
Aliment Pharmacol Ther. 2002 Jan;16(1):119-27
pubmed: 11856086
Crit Care Resusc. 2003 Mar;5(1):14-9
pubmed: 16573452
JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):99-105
pubmed: 1556825
Nutr Clin Pract. 2008 Dec;23(6):660-661
pubmed: 29130864
Crit Care Med. 2018 Dec;46(12):2036-2042
pubmed: 30222632
Anesth Analg. 2008 Mar;106(3):959-64, table of contents
pubmed: 18292446
Br J Pharmacol. 1993 Dec;110(4):1572-8
pubmed: 8306103
Arab J Gastroenterol. 2017 Mar;18(1):30-34
pubmed: 28262529
Intensive Care Med. 2013 May;39(5):899-909
pubmed: 23370829
Dig Liver Dis. 2008 Mar;40(3):188-93
pubmed: 18242155
Crit Care. 2014 Sep 23;18(5):502
pubmed: 25672546
Acta Inform Med. 2016 Dec;24(6):385-389
pubmed: 28077899